Anavex Life Sciences Corp. · NASDAQ:AVXL
Anavex Life Sciences — Investor Presentation (January 2026)
37 slides from Anavex Life Sciences's investor presentation, January 2026
Slide 1: Investor Presentation January 2026
Investor Presentation January 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements made within the meaning of the Private Securities Litigation Reform Act of 1995 by Anavex® Life Sciences Corp. and its representatives. These statements can be identified by introductory words such as “expects,” “plans,
Slide 3: Mission: advancing brain health with innovative oral medicines
“We are dedicated to advancing brain health by developing innovative oral medicines designed to improve patient lives.” 3
Slide 4: Transforming Brain Health Through Personalized Oral Medicine
Transforming Brain Health Through Personalized Oral Medicine Broad Personalized Multiple pipeline with brain medicine upcoming first-in-class approach potential milestones Mission to transform brain health through improved Patient- oriented Strong IP patient outcomes by therapies, portfolio developi
Slide 5: Alzheimer's – Worldwide Dementia Cases Projected to Reach 139M by 2050
Alzheimer’s – Worldwide Dementia Cases Projected to Reach to 139M by 2050 Addressing growing burden with convenient oral once-daily commercially scalable potential medicine Anavex to potentially capitalize on significant and growing market opportunity to treat CNS diseases 5 Source: World Alzheimer’
Slide 6: Blarcamesine Clinically Meaningful Improvements On Top Of Standard Of Care
Blarcamesine Clinically Meaningful Improvements On Top Of Standard Of Care1 Blarcamesine significantly slowed patient-relevant cognitive decline in Phase IIb/III trial 2: • Significantly slowed clinical progression by 36.3% at week 48 as well as the prespecified patient group (~70% of population) by
Slide 7: Patients and Caregivers: Strong Preference for Oral Treatment
Patients and Caregivers: Strong Preference for Oral Treatment Preference for oral dosage form of Evaluation of the accessibility of oral disease modifying treatments (DMTs) treatment as ‘very convenient' 100% 100% 84.9% 89% % of surveyed patients and caregivers1 agree European patients and caregiver
Slide 8: Potential to Unlock Substantial Commercial Opportunity to Drive Shareholder Value
Potential to Unlock Substantial Commercial Opportunity to Drive Shareholder Value Discussions with regulatory agencies in key markets in progress with the objective to determine potential pathways to obtain marketing authorization Broad IP protection in key markets for product candidates up to 2040
Slide 9: Broad Portfolio of Potential Cost Effective and Safe Treatments for CNS Conditions
Broad Portfolio of Potential Cost Effective and Safe Treatments for CNS Conditions Oral Solid Oral Liquid Oral Solid Patient ANAVEX®2-73 (blarcamesine) ANAVEX®2-73 (blarcamesine) ANAVEX®3-71 (AF710B) Preference Strong preference for oral • Alzheimer’s Disease • Rett Syndrome • Schizophrenia therapie
Slide 10: Progressing Pipeline with Multiple Milestones Towards Potential Commercialization
Progressing Pipeline with Multiple Milestones Towards Potential Commercialization CANDIDATE PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMPASSIONATE USE ANAVEX®2-73 ALZHEIMER’S DISEASE ANAVEX®2-73-002/3 ANAVEX®2-73-AD-006 ANAVEX®2-73-AD-004 ANAVEX®2-73-AD-005 AD AN AVEX ®2-73-AD-004 OLE / COMPASSIONATE USE
Slide 11: Autophagy: An Upstream Therapeutic Intervention in Alzheimer's Disease
Autophagy: An Upstream Therapeutic Intervention in Alzheimer’s Disease Neural autophagy weakens with aging, and ‘clean-up’ diminishes further in patients with neurodegenerative diseases1,2,3 Oral blarcamesine acts as a re-activator of neural autophagy 1. Gómez, O et al. “Autophagy and Glycative Stre
Slide 12: Autophagy Platform Shows Promise for Advanced Care
Autophagy Platform Shows Promise for Advanced Care Anavex portfolio positioned to target significant unmet medical need across multiple CNS conditions Achieved Near Term Long Term Autophagy through SIGMAR1 activation Autophagy through SIGMAR1 technology to Potential expansion into future opportuniti
Slide 13: Phase IIb/III Oral Blarcamesine for Early Alzheimer's Disease
Phase IIb/III Oral Blarcamesine for Early Alzheimer’s Disease 13
Slide 14: Mechanism of Oral Blarcamesine in Early Alzheimer's Disease
Mechanism of Oral Blarcamesine in Early Alzheimer’s Disease 14
Slide 15: Alzheimer's Disease Progression
Alzheimer's Disease Progression Impairment of autophagy precedes both amyloid beta and tau tangles, and therefore anticipates the neurodegenerative process in Alzheimer’s disease 1,2 Impaired Autophagy • Lysosomal and Synaptic Dysfunction Amyloid Beta Accumulation • APP Processing Tau Tangles • Micr
Slide 16: Blarcamesine Mechanism of Action Enhanced-Restored Autophagy
Blarcamesine Mechanism of Action Enhanced-Restored Autophagy1 GABARAP: key autophagy protein LC3: key autophagy protein blarcamesine LC3: microtubule-associated protein 1 light chain 3 LIR: LC3-Interacting Region 𝛥LIR: pointmutation of LIR ER: Endoplasmic Reticulum ✚: Switch-on of autophagy with…
Slide 17: Alzheimer's Disease Pathology Manifested in Volume Loss (Atrophy) of the Brain
Alzheimer’s Disease Pathology Manifested in Volume Loss (Atrophy) of the Brain Brain volume loss (atrophy) in Alzheimer’s disease1 NORMAL ALZHEIMER’S DISEASE 17 1. Exemplified by defying dememtia lancaster.ac.uk/defyingdementia
Slide 18: Reduced Atrophy of the Brain in Blarcamesine-treated Patients Compared to Placebo
Reduced Atrophy of the Brain in Blarcamesine-treated Patients Compared to Placebo Significant slowing of atrophy in broad brain regions after 48 weeks of treatment1 18 1. Macfarlane, S. et al. Blarcamesine for the treatment of Early Alzheimer’s Disease. J Prev Alzheimers Dis. 2025;12(1):100016.
Slide 19: Clinical Oral Blarcamesine Early Alzheimer's Disease Program
Clinical Oral Blarcamesine Early Alzheimer’s Disease Program 19
Slide 20: AD-004 Phase IIb/III Early Alzheimer's Disease Trial
AD-004 Phase IIb/III Early Alzheimer's Disease Trial Global, multi-center, double-blinded, placebo-controlled, parallel group, 48-week trial of once-daily oral blarcamesine1 ADAS-Cog13 LS Mean CDR-SB LS Mean Difference at Week 48 Difference at Week 48 2.5 0.7 • Enhanced clinical benefit of pre-speci
Slide 21: Significant Therapeutic Benefit of Blarcamesine Compared to ADNI Control Group over 144 Weeks
Significant Therapeutic Benefit of Blarcamesine Compared to ADNI Control Group over 144 Weeks Changes in ADAS-Cog13 AD-004/AD-EP-004 with ADNI Matched Control Clinical worsening Mean +/- SE of Change from Baseline ADAS-Cog13 Total Score DB/OLE ITT Population and Alzheimer’s Disease Neuroimaging Init
Slide 22: Extending the Dignity of Aging
Extending the Dignity of Aging Extended Time Saved1: • Patient-relevant outcome • Providing sustained patient benefit by maintaining functionality and independence 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI control group 1. ‘Time saved’ analysis of the ITT population
Slide 23: Future: Potential Prophylactic Effect of Blarcamesine
Future: Potential Prophylactic Effect of Blarcamesine 1 Blarcamesine demonstrated to be a potentially preventive treatment in the pharmacological model of Alzheimer's disease Blarcamesine significantly prevented aβ (abeta)-induced cognitive deficits with confirmed significant biomarker-response in a
Slide 24: Precision Medicine Approach with Oral Blarcamesine in Early Alzheimer's Disease
Precision Medicine Approach with Oral Blarcamesine in Early Alzheimer’s Disease 24
Slide 25: Ambition of New Precision Medicine Approach: Approximating Normal Cognitive Decline
Ambition of New Precision Medicine Approach: Approximating Normal Cognitive Decline as in Healthy Aging Adults • Highly heterogeneous and complex Alzheimer’s pathology supports Precision Medicine approach • Strong effect in identified SIGMAR1 WT population (~70%)1,2 • Autophagy mechanism specific to
Slide 26: Blarcamesine's Potential to Match Barely Detectable Prodromal Alzheimer's Disease Decline
Blarcamesine’s Potential to Match Barely Detectable Prodromal Alzheimer’s Disease Decline • Cognitive outcomes observed in the oral blarcamesine 30mg Precision Medicine ABCLEAR3 cohort, similar to referenced barely detectable prodromal AD decline1,2 • Strong treatment effect despite greater AD basel
Slide 27: Unprecedented Blarcamesine Effect Size Over Placebo in Large Specific Genetic Population
Unprecedented Blarcamesine Effect Size Over Placebo in Large Specific Genetic Population ADAS-Cog13 LS Mean Difference at Week 48 CDR-SB LS Mean Difference at Week 48 -5.0 -1.6 -4.5 -1.4 -4.0 -1.2 Increased Treatment Effect -3.5 -1.0 -3.0 -2.5 -0.8 -2.0 -0.6 -1.5 -0.4 -1.0 -0.2 -0.5 -0.0 -0.0 Blarca
Slide 28: Patient-Oriented Benefit: Self-Assessed Quality Of Life (QoL-AD)
Patient-Oriented Benefit: Self-Assessed Quality Of Life (QoL-AD) for Individuals with Alzheimer's Disease QoL-AD: What it measures: Physical health: Overall physical well-being. Energy: Level of energy and vitality. Mood: Emotional state and feelings. Living situation: Satisfaction with where the pe
Slide 29: Improvement in Self-Assessed QoL-AD Above Baseline with Blarcamesine
Improvement in Self-Assessed QoL-AD Above Baseline with Blarcamesine Increases in the Precision Medicine Cohorts Our Values ITT = Intent-to-Treat population (100% population), all available data points ABCLEAR1 = Alzheimer’s Blarcamesine Cognition Efficacy and Resilience gene variant non-carrier pop
Slide 30: Convenience of Blarcamesine in Early Alzheimer's Disease
Convenience of Blarcamesine in Early Alzheimer’s Disease 30
Slide 31: Patients and Families Continue to be the Center and Focus
Patients and Families Continue to be the Center and Focus Advantage for patient • Allowing direct access to new oral treatment • Focus on individual patient preference Advantage for family • Less stress for caregivers and less financial strain • No impact on own work schedule Advantage for physician
Slide 32: Large Patient-oriented, Identified, Accessible Opportunities
Large Patient-oriented, Identified, Accessible Opportunities 32
Slide 33: Addressing Actionable Patient Accessibility
Addressing Actionable Patient Accessibility Examining innovative strategies to effectively engage patients, providers and payers High demand from Alzheimer’s disease patients and families for easy access and scalable treatment options Intended to reduce the need for complex procedures for the treatm
Slide 34: Addressable CNS Diseases with Worldwide Commercial Rights and Global Opportunity
Addressable CNS Diseases with Worldwide Commercial Rights and Global Opportunity with Potential of Therapeutic Disruption U.S. AND GLOBAL PATIENT NUMBERS INDICATION USA EUROPE ASIA GLOBAL Alzheimer’s Disease (AD) 1,2 ~7,200,000 ~7,000,000 ~23,000,000 ~35,000,000 Parkinson’s Disease (PD) 3,4 ~1,000,0
Slide 35: Anavex' Strong Financial Profile Supports Operations; Funded for >3 Years
Anavex' Strong Financial Profile Supports Current Operations and Clinical Programs are Funded for >3 Years Strong balance sheet supported by non-dilutive Disciplined approach to funding sources operational expenditures $120M 39.0M Cash and cash equivalents1 Fiscal year 2025 cash utilization ~85.3M S
Slide 36: Focus on Patient-oriented Brain Medicines
Focus on Patient-oriented Brain Medicines • Late-stage Alzheimer’s program with scalable commercial opportunity in large market with huge unmet medical need • Emerging body of clinical data with blarcamesine suggests high efficacy in genetically defined large Alzheimer’s population through Precision
Slide 37: Contact Us
Contact Us Corporate Office Shareholder & Media Relations Anavex Life Sciences Corp. ir@anavex.com 630 5th Avenue, 20th floor www.anavex.com New York, NY 10111 NASDAQ: AVXL 1-844-689-3939
Anavex Life Sciences — Investor Presentation (January 2026) on 6ix